Liver disease: The effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation

Current Opinion in HIV and AIDS

Volumn 4, Issue 3, 2009, Pages 171-175

  Vogel, Martin ^a   Rockstroh, Jürgen K ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Antiretroviral therapy; Hepatitis coinfection; HIV

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; PEGINTERFERON ALPHA; TELBIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CONCURRENT INFECTION; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; EARLY INTERVENTION; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; PRIORITY JOURNAL; REVIEW; METHODOLOGY; TIME; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651174419     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328329c602     Document Type: Review

References (45)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739. (Pubitemid 27417972)
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29. (Pubitemid 36835816)
3. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45:1593-1601.
4. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14:183-188.
5. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002. (Pubitemid 41266795)
6. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601. (Pubitemid 40543982)
7. Hoffmann C, Seaberg E, D'Acunto K, et al. Death, HIV suppression, and CD4 recovery among HIV/HBV-co-infected men receiving ART: MACS [abstract 1029]. 15th Conference on Retroviruses and Opportunistic Infections; Washington, USA; 2008. This recent analysis of the Multicenter AIDS Cohort Study investigates into the long-term outcome of HAART in HIV/HBV-coinfected individuals. Response to HAART in terms of increment in CD4 cell count of suppression of HIV RNA was not influenced by HBV infection throughout a median follow-up of 8.5 years.
8. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058. (Pubitemid 29458296)
9. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216. (Pubitemid 350287219)
10. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133. (Pubitemid 38045883)
11. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008; 198:683-686. This study reports for the first time on liver biopsies in HIV-infected patients who had recently been infected with acute HCV. The authors report on 9/11 patients in whom advanced fibrosis was present despite a short time between estimated infection with HCV and liver biopsy.
12. Leslie DE, Rann S, Nicholson S, et al. Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria. Relationship with other blood borne viruses and liver disease. Med J Aust 1992; 156:789-792.
13. Schramm W, Roggendorf M, Rommel F, et al. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs. Blut 1989; 59:390-392. (Pubitemid 20050646)
14. Smit C, van den Berg C, Geskus R, et al. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008; 47:221-225. This paper describes a large and prospective study comparing, for the first time, the overall rates of survival between HCV-monoinfected and HIV/HCV-coinfected intravenous drug abusers. Although AIDS-related mortality decreased after 1997, liver-related death remained stable in HIV/HCV-coinfected patients and was higher compared with HCV-monoinfected patients. (Pubitemid 351172190)
15. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
16. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630. (Pubitemid 47436106)
17. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46:768-774. This reanalysis of the Ribavic trial investigated into the effect of pegylated interferon and ribavirin combination therapy on histologic changes in liver biopsies. In the mulitvariate analysis, didanosine use and not achieving sustained virological response were the only factors associated with a worsening of liver fibrosis.
18. Barreiro P, Labarga P, Martin-Carbonero L, et al. Sustained virological response following HCV therapy is associated with nonprogression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther 2006; 11:869-877. (Pubitemid 44736178)
19. Lacombe K, Boyd A, Lascoux-combe C, et al. The long term use of tenofovir disoproxil in HIV-HBV co-infection induces a marked decrease in liver fibrosis [abstract 914]. 59th AnnualMeeting of theAASLD; San Francisco,USA; 2008. This analysis is the first to document that antiviral therapy with tenofovir for the treatment of HBV in HIV/HBV-coinfected patients results in improvements of liver fibrosis and inflammation. Overall, 141 patients were followed either with fibroscan (n = 141) or paired liver biopsies (n = 38). After 12, 24 and 36 months of follow-up, a significant decrease in liver fibrosis was observed in patients with advanced fibrosis, whereas patients with minimal fibrosis at baseline remained stable.
20. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. These are the current treatment guidelines for HBV and HCV coinfection in HIV-positive individuals of the European AIDS Clinical Society. (Pubitemid 351228130)
21. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
22. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
23. Mallet VO, Dhalluin-Venier V, Verkarre V, et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 2007; 12:279-283.
24. Matthews GV, Cooper DA, Dore GJ. Improvements in parameters of endstage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther 2007; 12:119-122.
25. Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008; 22:947-955. (Pubitemid 351652245)
26. McDonald JA, Harris S, Waters JA, Thomas HC. Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol 1987; 4:337-342. (Pubitemid 17080472)
27. Marcellin P, Boyer N, Colin JF, et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993; 34 (Suppl 2):S106. (Pubitemid 23156103)
28. McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 7:719-723. (Pubitemid 17130712)
29. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108:165-171.
30. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570. These are the current treatment guidelines for the treatment of HIV-positive individuals of the IAS, USA.
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008:1-139. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed December 2008]. These are the current treatment guidelines for the treatment of HIV-positive individuals of the DHHS, USA.
32. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991. This meta-analysis investigated into the effect of HAART on liver fibrosis progression in HIV and hepatitis-coinfected individuals. Across trials, the development of liver fibrosis was attenuated by the use of HAART, although statistically, no significant influence was found.
33. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55. (Pubitemid 41772515)
34. Sterling R, Smith P, Wegelin J, et al. Prospective evaluation by paired liver biopsy of HCV disease progression in patients (pts) co-infected with HIV [abstract 27]. 59th Meeting of the AASLD; San Francisco, USA; 2008. In this paired biopsy study, interestingly, the rate of fibrosis progression in HIV/HCV-coinfected individuals was far lower than in a previous study by Sulkowski et al. [9].
35. Sandrine PF, Sylvie A, Andre E, et al. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 2007; 21:1498-1499.
36. Arey B, Markov M, Ravi J, et al. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007; 21:1066-1068. (Pubitemid 46684349)
37. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-192. (Pubitemid 46036926)
38. Tuyama A, Hong F, Mosoian A, et al. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: implications for hepatic fibrosis in HIV/HCV co-infection [abstract 57]. 15th Conference on Retroviruses and Opportunistic Infections; Washington, USA; 2008. This paper describes a very interesting in-vitro study demonstrating the possibility of HIV to enter hepatic stellate cells and induce collagen production and release of proinflammatory monocyte chemoattractant protein-1. It will be interesting to further understand, however, why not all HIV-infected patients develop liver fibrosis.
39. Macias J, Japon MA, Saez C, et al. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis 2005; 192:1566-1576. (Pubitemid 41504692)
40. Canchis PW, Yee HT, Fiel MI, et al. Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2004; 37:1125-1131.
41. Kuntzen T, Tural C, Li B, et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008; 22:203-210.
42. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
43. Bruno R, Sacchi P, Puoti M, et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 2007; 46:297-303. (Pubitemid 350287356)
44. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
45. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19:2117-2125.